Merck KGaA MKKGY
33.07 USD +0.45 (+1.38%)
Regular-session close
32.94 Day range 33.17
23.82 52-week range 34.10
- YTD
- +15.31%
- 1 year
- +17.31%
- Market cap
- 71.89B
- EPS (ttm)
- 1.29
- P/E ratio
- 25.64
- YTD return
- +15.31%
- 1-year return
- +17.31%
- Volume
- 4.92K
- Avg volume
- 87.57K
- Open
- 33.02
- Previous close
- 32.62
- Day's range
- 32.94 – 33.17
- 52-week range
- 23.82 – 34.10
5D -0.11 (-0.33%)
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2026 | Sep 30, 2026 | 0.46 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | 0.47 | 0.26 | -0.21 | -44.68% |
| May 13, 2026 | Mar 31, 2026 | 0.45 | 0.59 | +0.14 | +31.11% |
| Mar 5, 2026 | Dec 31, 2025 | 0.47 | 0.28 | -0.19 | -40.43% |
| Nov 13, 2025 | Sep 30, 2025 | 0.54 | 0.81 | +0.27 | +50.00% |
| Aug 7, 2025 | Jun 30, 2025 | 0.51 | 0.57 | +0.06 | +11.76% |
News
Merck KGaA (MKKGY) Q3 2026 Earnings Call Transcript 
Why Is Silence Therapeutics Stock Skyrocketing Monday? 
Qiagen M&A Fever Builds: KKR, EQT, Advent Explore Possible Takeover 
Acuity Posts Strong Q3 Results, Joins BlackBerry, MillerKnoll, Qualcomm And Other Big Stocks Moving Higher On Thursday 
Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges 
'Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say' - Reuters 
FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times 
Stocks That Hit 52-Week Highs On Tuesday - Stocks That Hit 52-Week Highs On Wednesday
- Stocks That Hit 52-Week Highs On Friday
Your note
Sign in to keep a note on MKKGY — it syncs with the Stock Master app.